Pulp Therapy
Vince Reynielle N. Labinpuno, DDS (he/him/his)
Pediatric Dentistry Resident
Hennepin Healthcare
Hennepin Healthcare
Minneapolis, Minnesota, United States
Amber Haskins, DMD (she/her/hers)
Pediatric Dental Resident
Hennepin County Medical Center
Hennepin County Medical Center
Bloomington, Minnesota, United States
David Watson, PhD
Children's Minnesota
Melanie Yuen, DMD
Faculty Attending
Hennepin Healthcare, Minneapolis, MN
Minneapolis, Minnesota, United States
Elisabeth Fulling, DDS
Program Director
Hennepin Healthcare
Minneapolis, Minnesota, United States
Purpose: The aim of this study is to determine if there are differences with overall, clinical, and radiographic success rates of pulpotomies using ferric sulfate, NeoMTA, or Biodentine completed at Hennepin Healthcare.
Methods: Pulpotomies on primary teeth that were completed at Hennepin Healthcare between 2016 and 2021 were chosen. Electronic medical records were reviewed and data were abstracted for the incident encounter and subsequent encounters. Participants were enrolled according to specific inclusion and exclusion criteria. Data recorded included demographic data, pre-treatment symptoms, treatment setting, medicament used (Ferric sulfate, NeoMTA, or Biodentine), and post-treatment clinical and radiographic findings. Primary endpoints include presence and date of clinical failure and/or radiographic failure. Data was recorded using REDCap then analyzed using survival analysis methods.
Results: A list of 563 subjects were identified via the dental code for pulpotomy (i.e. D3220). Of the 790 teeth enrolled, 435 pulpotomy treated teeth had clinical follow up and 325 teeth had post-treatment radiographs. At 36 months, the overall success rate of Biodentine, NeoMTA, and ferric sulfate were 98%, 94%, and 76%, respectively.
Conclusion: When all three medicaments were compared to one another, there is a statistically significant difference between the survival curves depicting overall (P=.004) and radiographic (P=.021) success rates.